Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients

被引:40
作者
Freedberg, Kenneth A.
Hirschhorn, Lisa R.
Schackman, Bruce R.
Wolf, Lindsey L.
Martin, Lindsay A.
Weinstein, Milton C.
Goldin, Susan
Paltiel, A. David
Katz, Carol
Goldie, Sue J.
Losina, Elena
机构
[1] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Ctr AIDS Res, Div AIDS, Boston, MA USA
[5] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Risk Anal, Boston, MA 02115 USA
[6] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[7] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA
[8] JSI Res & Training Inst, Boston, MA USA
[9] Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY USA
[10] Inst Healthcare Improvement, Cambridge, MA USA
[11] Yale Univ, Sch Med, New Haven, CT USA
[12] Cambridge Hlth Alliance, Zinberg Clin, Cambridge, MA USA
关键词
adherence; AIDS; HIV;
D O I
10.1097/01.qai.0000248334.52072.25
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Adherence to antiretroviral medications has been shown to be an important factor in predicting viral suppression and clinical outcomes. The objective of this analysis was to assess the cost-effectiveness of a nursing intervention on antiretroviral adherence using data from a randomized controlled clinical trial as input to a computer-based simulation model of HIV disease. For a cohort of HIV-infected patients similar to those in the clinical trial (mean initial CD4 count of 319 cells/mm(3)), implementing the nursing intervention in addition to standard care yielded a 63% increase in virologic suppression at 48 weeks. This produced increases in expected survival (from 94.5 to 100.9 quality-adjusted life months) and estimated discounted direct lifetime medical costs ($253,800 to $261,300). The incremental cost-effectiveness ratio for the intervention was $14,100 per quality-adjusted life year gained compared with standard care. Adherence interventions with modest effectiveness are likely to provide long-term survival benefit to patients and to be cost-effective compared with other uses of HIV care funds.
引用
收藏
页码:S113 / S118
页数:6
相关论文
共 51 条
[1]  
*AG HEALTHC RES QU, 2000, PUBL US INT DAT SET
[2]   Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication [J].
Altice, FL ;
Mezger, JA ;
Hodges, J ;
Bruce, RD ;
Marinovich, A ;
Walton, M ;
Springer, SA ;
Friedland, GH .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S376-S387
[3]   Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. [J].
Bozzette, SA ;
Joyce, G ;
McCaffrey, DF ;
Leibowitz, AA ;
Morton, SC ;
Berry, SH ;
Rastegar, A ;
Timberlake, D ;
Shapiro, MF ;
Goldman, DP .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :817-823
[4]  
*BUR CENS, 2003, STAT ABSTR US 2003
[5]   Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models [J].
Cole, SR ;
Hernán, MA ;
Robins, JM ;
Anastos, K ;
Chmiel, J ;
Detels, R ;
Ervin, C ;
Feldman, J ;
Greenblatt, R ;
Kingsley, L ;
Lai, SH ;
Young, M ;
Cohen, M ;
Muñoz, A .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 158 (07) :687-694
[6]   Directly observed therapy for the management of HIV-infected patients in a methadone program [J].
Conway, B ;
Prasad, J ;
Reynolds, R ;
Farley, J ;
Jones, M ;
Jutha, S ;
Smith, N ;
Mead, A ;
DeVlaming, S .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S402-S408
[7]  
de Klerk E, 2003, J RHEUMATOL, V30, P44
[8]  
Drummond M., 2015, METHODS EC EVALUATIO, V4
[9]  
Flexner Charles W, 2003, Top HIV Med, V11, P40
[10]   The cost-effectiveness of preventing AIDS-related opportunistic infections [J].
Freedberg, KA ;
Scharfstein, JA ;
Seage, GR ;
Losina, E ;
Weinstein, MC ;
Craven, DE ;
Paltiel, AD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (02) :130-136